Nadolol

A long-acting beta-blocker, FDA-approved for hypertension and long-term management of angina.

psilodex.org/m/nadolol · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~20–24 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Nadolol”, v2026.10.05. psilodex.org/m/nadolol

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Generic only in US

FDA-approved for

High blood pressure (hypertension)
Angina pectoris (long-term management)

Sources [1]

01 Interaction with psilocybin

It may lessen psilocybin's brief rise in heart rate and blood pressure. Separately, stopping it suddenly can worsen chest pain (angina).

Detail Nadolol is a beta-blocker that lowers blood pressure and heart rate. It may lessen psilocybin's brief rise in both, though there are no psilocybin data. It has a long half-life (20–24 h). Separately, stopping it suddenly can worsen angina (chest pain). Its label also warns that it can hide early signs of low blood sugar.

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~20–24 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Hypoglycemia risk: Can cause low blood sugar, especially if meals are missed or delayed. Sources [1]
Lowers blood pressure or causes orthostasis: Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Hypertension (provision applies if uncontrolled)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

Nadolol Tablets, USP (Amneal) · FDA label (DailyMed) — Withdrawal or rebound if stopped abruptly: Warnings: Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal "Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy." | Hypoglycemia risk: Warnings: Diabetes and Hypoglycemia "Beta blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment" | Lowers blood pressure or causes orthostasis: Indications and Usage "Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure." | Clinical Pharmacology "The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage." | revised 2026-05

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →